Markets:

Overview

News

Currencies

International

Treasuries

Cellectis S.A. - American Depositary Shares (NQ:CLLS)

3.580 +0.220 (+6.55%)

Streaming Delayed Price Updated: 10:11 AM EDT, Apr 8, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Cellectis S.A. - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 Next >

Why Tesla Shares Are Trading Lower; Here Are 32 Stocks Moving Premarket ↗

January 03, 2023

Gainers

Via Benzinga

Mayflower Bioventures Launches its First Spin-Out, Primera Therapeutics, in Strategic Collaboration with Cellectis to Develop a Gene Editing Platform to Treat Mitochondrial Diseases

December 29, 2022

From Cellectis Inc.

Via GlobeNewswire

Cellectis secures a €40 million credit facility from the European Investment Bank to support its Research, Development and Innovation activities

December 28, 2022

From Cellectis Inc.

Via GlobeNewswire

Cellectis Touts Positive Preliminary Data From Two Leukemia Trials ↗

December 13, 2022

Via Benzinga

Cellectis Announces First Dosing of a Patient with its In-house Manufactured Product Candidate UCART22 for the treatment of r/r B-cell ALL

December 22, 2022

From Cellectis Inc.

Via GlobeNewswire

Crispr Stock In 2023: Will Down-In-The-Dumps Shares Sparkle Again In 2023? ↗

December 22, 2022

Crispr and Vertex are working toward the first submissions for a CRISPR-based product.

Via Investor's Business Daily

Cellectis Announces Positive Preliminary Clinical Data for UCART22 in ALL and UCART123 in AML

December 13, 2022

From Cellectis Inc.

Via GlobeNewswire

Cellectis to Host a Live Webcast and Provide a Company Update on December 13, 2022

December 01, 2022

From Cellectis Inc.

Via GlobeNewswire

Cellectis Presents Pre-Clinical Data on TALEN®-edited Smart CAR T-cells Overcoming Key Challenges of Targeting Solid Tumors at SITC 2022

November 10, 2022

From Cellectis Inc.

Via GlobeNewswire

Cellectis Publishes Manuscript in Frontiers Bioengineering and Biotechnology Unveiling Efficient Multitool/Multiplex Gene Engineering combining TALEN® and TALE Base Editors (TALE-BE)

November 10, 2022

From Cellectis Inc.

Via GlobeNewswire

Cellectis Provides Business Update and Reports Financial Results for Third Quarter and First Nine Months 2022

November 03, 2022

From Cellectis Inc.

Via GlobeNewswire

Cellectis to Showcase Clinical Data from AMELI-01 and Preclinical Data from UCARTCS1 at ASH 2022

November 03, 2022

From Cellectis Inc.

Via GlobeNewswire

Cellectis's Earnings Outlook ↗

November 02, 2022

Cellectis (NASDAQ:CLLS) is set to give its latest quarterly earnings report on Thursday, 2022-11-03. Here's what investors need to know before the announcement. Analysts estimate that Cellectis will...

Via Benzinga

Cellectis to Report Third Quarter 2022 Financial Results

October 27, 2022

From Cellectis Inc.

Via GlobeNewswire

Cellectis Presents Data on Two TALEN®-based Gene Therapy Preclinical Programs for Patients with Sickle Cell Disease and Mucopolysaccharidosis type I at ESGCT 2022

October 11, 2022

From Cellectis Inc.

Via GlobeNewswire

Why Missfresh Shares Are Trading Lower; Here Are 30 Stocks Moving Premarket ↗

October 10, 2022

Gainers M-tron Industries, Inc. (NASDAQ: MPTI) rose 57.9% to $24.00 in pre-market trading after surging 10% on Friday. M-tron Industries completed its earlier announced separation from The LGL Group,...

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

October 07, 2022

Gainers Akanda (NASDAQ:AKAN) stock rose 27.1% to $0.52 during Friday's pre-market session. The company's market cap stands at $16.0 million.

Via Benzinga

Cellectis to Present Pre-Clinical Data on TALEN®-edited Smart CAR T-cells Supporting Improved Solid Tumor Targeting at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting

October 05, 2022

From Cellectis Inc.

Via GlobeNewswire

Cellectis Appoints Mark Frattini, M.D., Ph.D. as Chief Medical Officer

September 28, 2022

From Cellectis Inc.

Via GlobeNewswire

11 Health Care Stocks Moving In Friday's Pre-Market Session ↗

September 23, 2022

Gainers Rubius Therapeutics (NASDAQ:RUBY) shares moved upwards by 30.46% to $0.59. The market value of their outstanding shares is at $53.5 million.

Via Benzinga

Why NanoVibronix Shares Surged Over 25%; Here Are 82 Biggest Movers From Friday ↗

September 26, 2022

Gainers Golden Sun Education Group Limited (NASDAQ: GSUN) shares surged 92.1% to settle at $52.89 on Friday.

Via Benzinga

Why Shares Of Oil & Gas Companies Are Trading Lower, Here Are 62 Stocks Moving In Friday's Mid-Day Session ↗

September 23, 2022

Gainers Kiromic BioPharma, Inc. (NASDAQ: KRBP) shares jumped 87% to $0.4791. Kiromic BioPharma, said on Sept. 15, that the company received letter from the Nasdaq that co. has been granted 180-day...

Via Benzinga

Why T2 Biosystems Is Trading Higher By 18%; Here Are 28 Stocks Moving Premarket ↗

September 23, 2022

Gainers HHG Capital Corporation (NASDAQ: HHGC) shares rose 42.1% to $14.56 in pre-market trading.

Via Benzinga

Biotech Daily: Trial Setback For Eliem Therapeutics, Allarity Drops Work On Cancer Monotherapies, Axcella Aces Long COVID Study ↗

August 02, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Recap Of Monday's Biotech Catalysts - End Of the Day Summary ↗

August 01, 2022

Via Benzinga

Cellectis Gets FDA Nod For Initial-Stage Non-Hodgkin Lymphoma Study ↗

August 01, 2022

The U.S. Food and Drug Administration (FDA) has announced clearance to Cellectis' (NASDAQ: CLLS) Investigational New Drug (IND) application to initiate a Phase 1/2a clinical trial of UCART20x22 for...

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

July 14, 2022

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

June 22, 2022

Via Benzinga

71 Biggest Movers From Yesterday ↗

May 20, 2022

Gainers NeuroMetrix, Inc. (NASDAQ: NURO) shares jumped 76.3% to close at $5.50 on Thursday after the company announced the FDA has granted De Novo authorization to market the Quell neuromodulation...

Via Benzinga

38 Stocks Moving In Thursday's Mid-Day Session ↗

May 19, 2022

Gainers NeuroMetrix, Inc. (NASDAQ: NURO) shares climbed 34.6% to $4.1993 after the company announced the FDA has granted De Novo authorization to market the Quell neuromodulation device as an aid for...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.